May 25, 2016
Sunovion drug improves depressive symptoms
By Laura Finaldi
Marlborough-based Sunovion Pharmaceuticals announced a drug used to treat schizophrenia and bipolar depression was well-tolerated in patients and was associated with improved depressive symptoms in a secondary analysis.
The drug Latuda, when taken once a day for six months following a six-week placebo controlled treatment period, was well tolerated with small changes in metabolic parameters, Sunovion's study found. A secondary analysis found the drug to be associated with improvement in depressive symptoms, based on observed case data over time and assessed using a depression rating scale.
The results from the six-month, open-label extension study were published the journal Depression and Anxiety, the company announced Monday. The study was designed to evaluate the drug’s long-term safety potential in patients with bipolar depression and tested Latuda both alone and as an adjunctive therapy, according to the company.
CORRECTION: A previous version of this article incorrectly stated that Latuda was well tolerated with small changes in weight and metabolism. This has been changed to say "metabolic parameters."
WBJ Web Partners
Most Recent
Most Recent
0 Comments